Bullfrog AI Holdings Common Stock logo

Bullfrog AI Holdings Common StockNASDAQ: BFRG

Profile

Sector:

Healthcare

Country:

United States

IPO:

13 February 2023

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$18.21 M
-65%vs. 3y high
23%vs. sector
-vs. 3y high
-vs. sector
-72%vs. 3y high
80%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | 14 min ago
$2.09+$0.06(+2.96%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

BFRG Latest News

BullFrog AI's VP Artificial Intelligence to Present at Google's Cancer AI Symposium
globenewswire.com22 October 2024 Sentiment: POSITIVE

GAITHERSBURG, Md., Oct. 22, 2024 (GLOBE NEWSWIRE) -- BullFrog AI, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced its VP Artificial Intelligence, Enrique García-Rivera, Ph.D., will present at Google's inaugural Cancer AI Symposium on October 30, 2024, at the Boston Center for the Arts.

WallachBeth Capital Announces Closing of Bullfrog AI Registered Direct Offering and Concurrent Private Placement for Aggregate Gross Proceeds of $3.13 Million
prnewswire.com21 October 2024 Sentiment: POSITIVE

JERSEY CITY, N.J. , Oct. 21, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, announced today it has closed its previously announced definitive agreement for the purchase and sale of an aggregate of 1,565,000 shares of common stock (or common stock equivalents in lieu thereof) in a registered direct offering and, in a concurrent private placement, common warrants to purchase up to 1,565,000 shares of common stock (together with the registered direct offering) at a combined purchase price of $2.00.

Bullfrog AI Announces Closing of Registered Direct Offering and Concurrent Private Placement for Aggregate Gross Proceeds of $3.13 Million
globenewswire.com21 October 2024 Sentiment: POSITIVE

GAITHERSBURG, Md., Oct. 21, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, announced today it has closed its previously announced definitive agreement for the purchase and sale of an aggregate of 1,565,000 shares of common stock (or common stock equivalents in lieu thereof) in a registered direct offering and, in a concurrent private placement, common warrants to purchase up to 1,565,000 shares of common stock (together with the registered direct offering) at a combined purchase price of $2.00. The warrants will have an exercise price of $2.00 per share, are initially exercisable on the date that is six months from the date of issuance and will expire five years from such initial exercise date.

Bullfrog AI Announces Pricing of Registered Direct Offering and Concurrent Private Placement for Aggregate Gross Proceeds of $3.13 Million
globenewswire.com18 October 2024 Sentiment: POSITIVE

GAITHERSBURG, Md., Oct. 18, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, announced today it has entered into a definitive agreement for the purchase and sale of an aggregate of 1,565,000 shares of common stock (or common stock equivalents in lieu thereof) in a registered direct offering and, in a concurrent private placement, common warrants to purchase up to 1,565,000 shares of common stock (together with the registered direct offering) at a combined purchase price of $2.00. The warrants will have an exercise price of $2.00 per share, are initially exercisable on the date that is six months from the date of issuance and will expire five years from such initial exercise date.

WallachBeth Capital Announce Pricing of Bullfrog AI's Registered Direct Offering and Concurrent Private Placement for Aggregate Gross Proceeds of $3.13 Million
prnewswire.com18 October 2024 Sentiment: POSITIVE

JERSEY CITY, N.J. , Oct. 18, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, has entered into a definitive agreement for the purchase and sale of an aggregate of 1,565,000 shares of common stock (or common stock equivalents in lieu thereof) in a registered direct offering and, in a concurrent private placement, common warrants to purchase up to 1,565,000 shares of common stock (together with the registered direct offering) at a combined purchase price of $2.00.

BullFrog AI Announces Publication of Data Supporting Potential of Liver Disease Treatment Candidate BF-114
globenewswire.com09 October 2024 Sentiment: POSITIVE

GAITHERSBURG, Md., Oct. 09, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the publication of new research in the peer-reviewed journal Cell Reports supporting the potential of BullFrog AI's drug candidate, BF-114 (SPTBN1 siRNA), in treating a range of liver diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), and hepatocellular carcinoma (HCC). The research was generated in a study led by Lopa Mishra, MD, professor of medicine, Merinoff Endowed Chair and co-director of the Institute for Bioelectronic Medicine at Feinstein Institutes for Medical Research at Northwell Health, Cold Spring Harbor Laboratory.

BullFrog AI and Lieber Institute for Brain Development Reveal New Insights into Bipolar Disorder Pathways and Potential Drug Targets
globenewswire.com25 July 2024 Sentiment: POSITIVE

Discussions underway for drug target discovery deals with potential pharma partners Discussions underway for drug target discovery deals with potential pharma partners

Join BullFrog AI's Exclusive Live Investor Webinar and Q&A Session on June 12
globenewswire.com29 May 2024 Sentiment: POSITIVE

GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) -- BullFrog AI, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, is pleased to invite investors to a webinar on June 12, 2024, at 4:15 p.m. ET.

BullFrog AI and Lieber Institute for Brain Development Collaboration Identifies Novel Drug Targets for Neuropsychiatric Disorders
globenewswire.com16 May 2024 Sentiment: POSITIVE

BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company") announced today that it has made significant progress in its partnership with the Lieber Institute for Brain Development (LIBD), identifying potential drug targets for various neuropsychiatric disorders.

Bullfrog AI: advancing technologies in leaps and bounds
MarketBeat19 January 2024 Sentiment: POSITIVE

If Bullfrog AI NASDAQ: BFRG is not on your radar yet, it should be. This company is an emerging leader in a subset of AI that will have one of the furthest-reaching impacts on humanity: drug discovery.

  • 1(current)

What type of business is Bullfrog AI Holdings Common Stock?

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.

What sector is Bullfrog AI Holdings Common Stock in?

Bullfrog AI Holdings Common Stock is in the Healthcare sector

What industry is Bullfrog AI Holdings Common Stock in?

Bullfrog AI Holdings Common Stock is in the Health Information Services industry

What country is Bullfrog AI Holdings Common Stock from?

Bullfrog AI Holdings Common Stock is headquartered in United States

When did Bullfrog AI Holdings Common Stock go public?

Bullfrog AI Holdings Common Stock initial public offering (IPO) was on 13 February 2023

What is Bullfrog AI Holdings Common Stock website?

https://www.bullfrogai.com

Is Bullfrog AI Holdings Common Stock in the S&P 500?

No, Bullfrog AI Holdings Common Stock is not included in the S&P 500 index

Is Bullfrog AI Holdings Common Stock in the NASDAQ 100?

No, Bullfrog AI Holdings Common Stock is not included in the NASDAQ 100 index

Is Bullfrog AI Holdings Common Stock in the Dow Jones?

No, Bullfrog AI Holdings Common Stock is not included in the Dow Jones index

When was Bullfrog AI Holdings Common Stock the previous earnings report?

No data

When does Bullfrog AI Holdings Common Stock earnings report?

Next earnings report date is not announced yet